It is also possible that this high background proliferation in the PLT2 mice might limit the ability of the Poly I:C treatment to further expand the antigen specific CD8+ T cell population sufficiently to raise an effective anti-tumor immune response. The gene discussed is CD8A; the disease is neoplasm.